Pharmaceutical Executive-10-01-2021

How can large pharma improve D&I in its companies?

Evaluating patient data in the context of complementary information can provide comprehensive market insights for product strategy.

COVID may have given real-world evidence the boost it needed to become routine, especially in areas that demand research innovation and advancement.

Our latest numbers crunch on biopharma financial performance—this one assessing growth and value-generation during the heart of COVID-19—reveals a mix of the familiar and new entrants into the top spots in seven business-critical metrics.

Unconventional collaborations between biopharma and tech are starting to take off.

While there is broad agreement that the Chief Data Officer plays a critical part in pharma, a definitive description of the role is still evolving.

Imvax CEO John Furey taps into tried-and-true powers of hope and clarity as he moves the clinical stage biotech from single program to platform company.

While Q3 numbers look bleak, is improvement on the horizon?

Emerging limits of one-year payer time frames.

How the sharing of scientific content with HCPs is shifting in an era of accelerated digitalization.

Soft skills are needed to round out the hard numbers.

New EU initiative aims to curve shortage of vaccines and therapies.

Looking Back at 2011–2014.

Examining the incumbent and imminent workforce.

Click the title above for a link to open the Pharmaceutical Executive October 2021 issue in an interactive PDF format.

Critics say FDA is either acting too fast and risking public safety—or too slow, mired in rules while ignoring important scientific findings.